Clinical Trials Sponsored by Lab Discoveries Ltd

Total 143 results

Lab Discoveries Ltd.

Unknown

Blood Test for Ovarian Cancer Associated Antibodies (CAAb)

Ovarian Cancer

Israel
Lab Discoveries Ltd.

Unknown

Breast Cancer Associated Antibodies

Breast Cancer

Israel
Karnataka Institute of Medical Sciences
Ministry of Science and Technology, India; Applied Genetics; Lab Discoveries...

Unknown

The Factors Associated With the Formation of Nasal polyp-a Case Control and Descriptive Study (ACAAGSONP)

Smoking | Allergic Rhinitis | Rhinosinusitis | Deviated Nasal Septum | Nasal Polyp | ASA Intolerant Asthma

India
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient

Platinum-sensitive Relapsed Ovarian Cancer

China
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

Gastrointestinal Stromal Tumor(GIST)

China
Zai Lab (Shanghai) Co., Ltd.

Terminated

MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

Advanced Hepatocellular Carcinoma (HCC)

China
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Unresectable, Recurrent or Metastatic Melanoma | Untreated Mucosal or Acral Lentiginous Melanoma

China
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Breast Cancer Metastatic

Taiwan
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumors

China
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

Ovarian Cancer

China
Zai Lab Pty. Ltd.

Unknown

Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects

Chronic Obstructive Pulmonary Disease | Asthma | Idiopathic Pulmonary Fibrosis

Australia
Zai Lab (Shanghai) Co., Ltd.

Completed

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Solid Malignancies

China
Zai Lab (Shanghai) Co., Ltd.

Completed

A Trial of ZL-1201 in Subjects With Advanced Cancer

Advanced Cancer

United States, China
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Gastric Cancer | Triple Negative Breast Cancer | Endometrial Carcinoma | Biliary Tract Carcinoma

China
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

HER2 Positive Metastatic Breast Cancer

China
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Ovarian Cancer

China
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

China
Zai Lab (Shanghai) Co., Ltd.

Completed

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Hepatocellular Carcinoma (HCC)

China
Zai Lab (Shanghai) Co., Ltd.

Completed

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

Ovarian Cancer

China
Zai Lab Pty. Ltd.

Completed

Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema

Eczema

China
Zai Lab (Shanghai) Co., Ltd.
Zai Lab (US) LLC

Recruiting

An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer

SCLC

United States
Zai Lab (Hong Kong), Ltd.

Recruiting

A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP (public)

Community-acquired Bacterial Pneumonia

United States
Lustre Pharmaceutical Lab Co., Ltd

Unknown

An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD

Chronic Obstructive Pulmonary Disease
argenx
Zai Lab Pty. Ltd.

Recruiting

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Primary Membranous Nephropathy (ZL-1103-014)

Membranous Nephropathy

China
Lustre Pharmaceutical Lab Co., Ltd

Unknown

A Pharmacodynamic and Safety Study of BCS in Healthy Volunteers

Healthy Volunteers

China
Zai Lab (Shanghai) Co., Ltd.
Mirati Therapeutics Inc.

Active, not recruiting

The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors

Advanced or Metastatic Solid Tumor

China
Zai Lab (Hong Kong), Ltd.
Zai Lab (US) LLC

Not yet recruiting

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

Plaque Psoriasis

Australia, Canada
Apex Labs Ltd.

Not yet recruiting

Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD (SUMMIT-90)

Depression | Post-traumatic Stress Disorder
ILAb Co., Ltd.

Completed

SAD Study of IA-14069

Healthy

United States
ILAb Co., Ltd.

Recruiting

MAD Study of IA-14069

Healthy | Rheumatoid Arthritis

United States
Inspir Labs Ltd.

Recruiting

Safety and Usability of the LUMENA Non-invasive Ventilation Mask

Respiratory Failure

Israel
Biotax Labs LTD

Recruiting

Microbiome Test for the Detection of Colorectal Polyps

Colon Polyp

Israel
argenx
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

Lupus Nephritis

China
MacroGenics
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)

Gastric Cancer | Gastroesophageal Junction Cancer | HER2-positive Gastric Cancer

Korea, Republic of, United States, China, Italy, Taiwan, Germany, Singapore, United Kingdom, Poland
NovoCure GmbH
Zai Lab (Shanghai) Co., Ltd.

Unknown

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Gastric Cancer | GastroEsophageal Cancer

Hong Kong
Zai Biopharmaceutical (Suzhou) Co., Ltd.

Recruiting

A Study of ZL-1211 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

United States, China
Lai Corporation Pty. Ltd.

Unknown

The Effects of AMPC in the Treatments of Refractory or Relapsed AML (AMPCAL)

Acute Myeloid Leukaemia Recurrent

Thailand
Karuna Therapeutics
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia (UNITE-001)

Schizophrenia

China
Incyte Corporation
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

Metastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung Cancer

China, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
Bristol-Myers Squibb
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Carcinoma, Non-Small-Cell Lung

Japan, China, Spain, Germany, Korea, Republic of, Austria, Brazil, Romania, France, United States, Italy, Argentina, Canada, Chile, Greece, Hungary, India, Poland, Turkey, Switzerland, Netherlands
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

Healthy Adult Subjects

United States
ResMed
SleepScore Labs International LTD

Recruiting

The Effects of a Personalized Sleep Improvement App From SleepScore Labs

Health Behavior

Germany
I-Mab Biopharma Co. Ltd.

Recruiting

Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

Gastric Cancer | Solid Tumor | Metastatic Cancer | Advanced Cancer | Esophageal Adenocarcinoma | Gastroesophageal Junction Carcinoma

United States, China
I-Mab Biopharma Co. Ltd.

Recruiting

A Study of TJ003234 in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

China
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

Solid Tumor | Metastatic Cancer | Advanced Cancer

United States
I-Mab Biopharma Co. Ltd.

Recruiting

A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019 COVID-19

United States
I-Mab Biopharma Co. Ltd.

No longer available

Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001

Solid Tumor Metastatic Cancer Advanced Cancer
Turning Point Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, China, Japan, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, Korea, Democratic People's Republic of, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom
Five Prime Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)

Gastric Cancer

United States, Spain, China, Italy, Korea, Republic of, Portugal, Taiwan, Japan, Turkey, France, Hungary, Thailand, Germany, Poland, Australia, Belgium, Romania, United Kingdom

Clinical Trials Sponsored by Lab Discoveries Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations